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Identification of immediate early gene products of bovine
herpes virus 1 (BHV-1) as dominant antigens recognized by
CD8 T cells in immune cattle
Jane Hart,1 Niall D. MacHugh,1 Tara Sheldrake,1 Morten Nielsen2 and W. Ivan Morrison1,3,*
Abstract
In common with other herpes viruses, bovine herpes virus 1 (BHV-1) induces strong virus-specific CD8 T-cell responses.
However, there is a paucity of information on the antigenic specificity of the responding T-cells. The development of a system
to generate virus-specific CD8 T-cell lines from BHV-1-immune cattle, employing Theileria-transformed cell lines for antigen
presentation, has enabled us to address this issue. Use of this system allowed the study to screen for CD8 T-cell antigens
that are efficiently presented on the surface of virus-infected cells. Screening of a panel of 16 candidate viral gene products
with CD8 T-cell lines from 3 BHV-1-immune cattle of defined MHC genotypes identified 4 antigens, including 3 immediate
early (IE) gene products (ICP4, ICP22 and Circ) and a tegument protein (UL49). Identification of the MHC restriction
specificities revealed that the antigens were presented by two or three class I MHC alleles in each animal. Six CD8 T-cell
epitopes were identified in the three IE proteins by screening of synthetic peptides. Use of an algorithm (NetMHCpan) that
predicts the peptide-binding characteristics of restricting MHC alleles confirmed and, in some cases refined, the identity of
the epitopes. Analyses of the epitope specificity of the CD8 T-cell lines showed that a large component of the response is
directed against these IE epitopes. The results indicate that these IE gene products are dominant targets of the CD8 T-cell
response in BHV-I-immune cattle and hence are prime-candidate antigens for the generation of a subunit vaccine.
INTRODUCTION
Infection with herpes viruses typically results in an acute
lytic phase of virus replication, which may be associated
with clinical symptoms, followed by establishment of latent
infection that can persist for many years. Latently infected
cells express only a few genes, but reactivation can occur,
often triggered by stress or immunosuppression, whereby
expression of the full complement of viral genes is restored,
resulting in the production of infectious virus. CD8 T-cell
responses have been shown to be important mediators of
immunity to a number of herpesvirus infections. There is
compelling evidence that they are required to prevent reacti-
vation of latent infection and that they also contribute to
resolution of the acute phase of infection [1, 2]. The promi-
nent role of CD8 T cells in immunity is also consistent with
the capacity of herpesviruses, including bovine herpes virus
1 (BHV-1), to inhibit a number of the steps involved in
processing and presentation of antigen to CD8 T cells [3, 4],
thus reducing the efficiency of the CD8 T-cell response.
The capacity of CD8 T cells to act as effectors against viral
infections relies on their ability to recognize and respond to
virus-infected cells before they produce large quantities of
virus. Herpesviruses are antigenically complex, encoding
between 70 and 165 proteins, synthesis of which is regulated
in a cascade fashion, with immediate early (IE) genes being
expressed first, followed by early (E) and late (L) genes. The
IE and E proteins are involved in regulating expression of
other viral genes or modulation of host cell function,
whereas products encoded by the L genes are generally
structural components of the virion. Knowledge of which
categories of viral protein are recognized by the CD8 T-cell
response and the ability of the specific CD8 T cells to recog-
nize virus-infected cells can inform the choice of antigens
for inclusion in new vaccines.
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Among human herpes viruses, the antigenic specificity of
CD8 T-cell responses has been studied most extensively for
cytomegalovirus (CMV), Epstein–Barr virus (EBV) and her-
pes simplex viruses 1 and 2 (HSV-1 and HSV-2). Initial
studies suggested focusing of the CD8 T-cell responses on a
few dominant viral antigens, often including IE viral pro-
teins or (in the case of EBV) latent gene products [5, 6].
Subsequent use of more comprehensive antigen screening
methods [7, 8] has revealed CD8 T cells specific for a large
number of viral antigens [9–12], including IE, E and L gene
products. However, certain proteins tend to be recognized
more consistently and generate stronger responses than
others, eg. pp65 and IE1 in CMV [13]. Analyses of CD8 T
cells from humans infected with herpes simplex virus type 1
(HSV-1), an alpha herpesvirus most closely related to BHV-
1, have identified CD8 T-cell reactivity with over half the
viral proteins, including proteins with diverse expression
dynamics [7, 8]. However, the relative capacities of the dif-
ferent CD8 T-cell specificities to recognize virus-infected
cells and act as immune effectors remain unclear.
Bovine herpesvirus type 1 (BHV-1) is the most widely dis-
tributed pathogenic herpesvirus of cattle. BHV-1 infects
cells of the respiratory and reproductive tracts and causes
clinical diseases, namely infectious bovine rhino-tracheitis
and infectious pustular vulvo-vaginitis [14], which result in
significant production losses in affected herds, including the
death of some animals. BHV-1-encoding proteins have a
number of immunomodulatory activities, including down-
regulation of type I interferon responses [15] and expression
of class I MHC proteins [16], and interference with chemo-
kine activities [17], which collectively are associated with
suppressed cellular immune responses during infection.
This immunosuppression is implicated in predisposition to
secondary infections with other respiratory pathogens, both
viral and bacterial, which cause severe disease and mortality
in intensive cattle-rearing units (reviewed in [18]). Vaccina-
tion is widely deployed to control disease caused by BHV-1.
A number of inactivated and live attenuated vaccines are
commercially available, but the latter are more commonly
used because of the requirement for only one vaccine dose
(reviewed in [18, 19]). A vaccine using a virus containing a
deletion of the gene encoding gE is widely used at present;
in addition to being highly attenuated, this virus is incapable
of reactivation and its use allows differentiation of infected
from vaccinated animals based on detection of serological
responses to gE [20]. Although live vaccines have proved to
be relatively effective, concerns remain about their immuno-
suppressive activities and some of the most attenuated
viruses have been reported to have reduced immunogenicity
[20, 21]. Hence, there is continued interest in the possibility
of using subunit antigens for vaccination in some animal
production sectors. However, this is constrained by a pau-
city of information on potentially protective T-cell
responses elicited by BHV-1.
Although MHC class I-restricted CD8 T-cell responses have
been identified in animals immune to BHV-1 [22–24], little
is known about the specificity of these responses. This
appears to have been partly due to the poor sensitivity of
assays using ex vivo-derived T cells and the lack of reliable
in vitro systems for the maintenance and enrichment of
virus-specific CD8 T cells. Recently, we developed a system
to derive virus-specific CD8 T-cell lines from BHV-1-
immune cattle using Theileria annulata-transformed cell
lines infected with the virus as stimulator cells [25]. Herein
we describe the use of CD8 T-cell lines generated using this
system to identify CD8 T cell target antigens in BHV1. The
results demonstrate dominant responses to three IE BHV-1
early gene products.
RESULTS
Selection of viral antigens for T-cell screening
A panel of 16 BHV-1 genes, including four IE, four E and
eight L genes, was selected for antigen screening. The genes
and the PCR primers used for their amplification are listed
in Table S1 (available in the online Supplementary Mate-
rial). They include orthologues of genes known to encode
CD8 T-cell antigens in HSV-1 and genes encoding the gly-
coproteins gC and gD, which previous studies suggested
may be targets for the CD8 T-cell response to BHV-1 [24].
Cloned DNAs encoding each of these genes, inserted into
the pcDNA3.1V5 His TOPO eukaryotic expression vector,
were used for screening. The ICP4 gene-coding region was
cloned as two fragments overlapping by five codons
(nucleotides 1–2077 and 2061–4105), referred to herein as
ICP4-1 and ICP4-2, respectively.
Detection of antigens recognized by CD8 T cells
Unlike humans and mice, which generally express a fixed
complement of three class I genes, the number of
bovine class I genes expressed by different MHC haplotypes
varies between one and four [26]. The class I genes
expressed by a series of haplotypes in Holstein cattle have
been fully characterized, and full-length cDNAs in eukary-
otic expression vectors were available for the present study.
Three BHV-1-immune animals were used for antigen
screening, two of which expressed the A10 and A15 class I
MHC haplotypes, while one expressed the A11 and A14
haplotypes. All four haplotypes are present at relatively high
frequencies (~10%) in most populations in Holstein cattle
[27]. The MHC class I alleles expressed by the animals are
shown in Table 1. To detect which BHV-1 proteins were
recognized by these animals, a CD8 T-cell line from each
animal was screened for IFNg release following incubation
with COS-7 cells co-transfected with each BHV-1 gene and
a mixture of the class I MHC heavy-chain alleles expressed
by the respective CD8 T-cell line. The results obtained by
screening with CD8 T cells from one of the A10/A15 ani-
mals (3430) are illustrated in Fig. 1, which demonstrates
recognition of the expressed products of two IE genes, ICP4
and Circ. Identical results were obtained with the other
A10/A15 animal (3109). The A11/A14 animal (1475) also
recognized ICP4 and Circ and another IE gene product,
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ICP22, as well as an L gene (UL49) that encodes a tegument
protein (data not shown). The two A10/A15 animals recog-
nized both expressed fragments of the ICP4 gene (ICP4.1
and ICP4.2), indicating the presence of more than one epi-
tope specificity, whereas the A11/A14 animal only recog-
nized one fragment (ICP4.1).
Identification of the class I MHC restriction
elements
To determine which class I alleles are involved in presenta-
tion of the viral antigens, further screens were conducted in
which COS-7 cells were co-transfected with the viral genes
that gave positive reactions in the antigen screens, along
with individual class I heavy-chain cDNAs. The results are
shown in Figs 2 and 3 and the overall findings are summa-
rized in Table 1. Again, identical results were obtained with
the two A10/A15 animals; ICP4 was recognized in combina-
tion with both the 3*00102 (A10) and 1*00901 (A15) alleles,
and an additional positive reaction was detected with the
Circ gene product presented by 3*00102 (A10). No positive
reactions were detected against cells transfected with the
remaining class I alleles expressed by these animals
(2*01201, 4*02401 and 2*02501 – data not shown). In the
A11/A14 animal (1475), both ICP4 and UL49 were pre-
sented by the 3*01701 (A11) allele, Circ was presented by
the 2*01801 (A11) allele and ICP22 was presented by the
4*02401 (A14) allele. No positive reactions were detected
against cells transfected with the remaining class I alleles
expressed by this animal (1*02301, 2*02501 and 6*04001 –
data not shown). Thus in each animal individual antigens
are presented by one or two of the available class I alleles.
Identification of the CD8 T-cell epitopes in ICP4,
Circ and ICP22
Two parallel approaches were pursued to identify the epito-
pes in the three IE gene products recognized by CD8 T cells,
namely screening of truncated genes and synthetic peptides
for recognition by the T-cell lines, and in silico use of
Table 1. MHC class I genotypes of animals used for antigen screening
and BHV1 antigens detected
MHC allele Animals and MHC haplotypes Antigens
3109 and 3430 1475
A10 A15 A11 A14
2*01201 +
3*00201 + ICP4.1, Circ
1*00901 + ICP4.2
2*02501 + +
4*02401 + + ICP221
2*01801 + Circ
3*01701 + ICP4.1, UL49
1*02301 +
6*04001 +
1
Detected in animal 1475 but not in animals 3109 or 3430.
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Fig. 1. Results of antigen screening using a CD8 T-cell line from a
BHV-1-immune animal (3430 –MHCI A10/A15). T cells were incubated
with COS-7 cells that had been co-transfected with the individual BHV-
1 genes and a mixture of the MHCI cDNAs expressed by the donor ani-
mal. Release of IFNg into the culture supernatant was measured after
48 h using a specific ELISA. T cells incubated with autologous and allo-
geneic T. annulata-transformed cells infected with BHV-1 were
included as positive and negative controls, respectively.
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Fig. 2. MHC restriction of T-cell responses to BHV-1 proteins recog-
nized by a CD8 T-cell line from animal 1475 (MHCI A11/A14). T-cell
recognition was examined by incubation of T cells with COS-7 cells co-
transfected with individual BHV-1 genes and MHCI alleles and mea-
surement of IFNg release into the culture supernatant after 48 h using
a specific ELISA. Panels (a), (b) and (c) show the results obtained with
cells transfected with the 3*01701, 2*01801 and 4*02401 MHCI alleles,
respectively. None = COS-7 cells transfected with MHCI cDNA only;
BHV = autologous T. annulata-transformed cells infected with BHV-1.
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algorithms that predict the peptide-binding characteristics
of the restricting class I MHC alleles.
Epitope mapping
As a first step to epitope identification, a series of c-terminal
truncated versions of each of the viral genes, expressed in
COS-7 cells along with the relevant MHC alleles, were
screened to identify the epitope-containing regions of the
proteins. The results of these screens, summarized in
Table S2, enabled epitopes to be located within 38–117
amino acid segments of the proteins.
Overlapping synthetic (17-mer) peptides covering each pos-
itive region were then screened for T-cell recognition. The
results are shown in Figs S1 and S2. For each of the MHC-
antigen specificities, two contiguous overlapping peptides
were found to stimulate T-cell reactivity, suggesting the
presence of a single epitope.
Further fine mapping to identify the epitopes, defined as the
minimal length peptide that retained near-maximal T-cell rec-
ognition, was conducted using truncated peptides covering
the 17-mer peptides recognized by CD8 T cells. Similar results
were obtained with both A10/A15 animals. For the 1*00901-
restricted ICP4 epitope recognized by these animals, 12-mer,
11-mer, 10-mer, 9-mer and 8-mer peptides were used for
screening. The results obtained with the CD8 T-cell line from
animal 3019 (A10/A15) using the 12-mer and 9-mer peptides
are illustrated in Fig. 4, and they identify a 9-mer (ICP4 1159–
1167) as the likely epitope. Synthetic peptides representing
step-wise truncation at either end of the remaining positive
regions were used to map a further five epitopes; the results of
these screens are shown in Table 2. In each case, identification
of the C-terminal amino acid residue was relatively straight-
forward, as truncation at this residue resulted in an abrupt loss
of T-cell reactivity. By contrast, identification of the N-termi-
nal residues was in some cases more ambiguous. For example,
10-mer and 9-mer peptides for the ICP4-3*00201 and ICP22-
4*02401 epitopes (shown in Table 2) showed strong T-cell
recognition, but shorter 9-mer and 8-mer peptides truncated
by one residue at the N-terminus also retained substantial T-
cell recognition.
In silico validation
The identified epitope regions and the corresponding BoLA
restriction elements were analysed using the NetMHCpan
(version 2.9) prediction method [28]. Earlier studies have
demonstrated the ability of this method to accurately predict
peptides that bind to MHC I, including BoLA-1 molecules
[29–31], and the method has proved useful as a guide to con-
firm whether identified epitope sequences are indeed minimal
epitopes [32]. Therefore, these analyses set out to: (i) quantify
the degree to which in silico predictions are capable of identi-
fying the validated epitopes; and (ii) identify possible alterna-
tive peptide variants (extensions or fragments) of the validated
epitopes predicted to have improved binding affinity to the
BoLA-I restriction element. The results of the analyses, shown
in Table 3, reveal several important points. First and foremost,
they confirm the high predictive capacity of NetMHCpan for
most BoLA molecules. Four of the identified epitopes were
confirmed, including the ICP4-3*00201 AGPDLQLARL epi-
tope discussed above, which is predicted to have much stron-
ger MHC binding than the shorter peptide GPDLQLARL that
also showed T-cell recognition. In one case (ICP22-4*02401),
in silico screening suggested an alternative truncated version
(GAFCPEDW) of the epitope identified by peptide screening
(PGAFCPEDW); although the former showed slightly weaker
T-cell recognition, its superior predicted MHC binding indi-
cates that it is likely to represent the minimal epitope. Based
on these findings, in four out of six cases the F-rank value for
the (alternatively) validated epitopes is below 2%. The two
molecules with the poorest performance (BoLA-1*00901 and
BoLA-3*01701) both have protein sequences that are very
0
2
4
6
8
10
12
14
3*00201 2*01201 1*00901 4*02401 2*02501 BHV-1
IF
N
-g
 
(n
g
 m
l –
1
)
IF
N
-g
 
(n
g
 m
l –
1
)
IF
N
-g
 
(n
g
 m
l –
1
)
MHC class I gene  
(b)
0
2
4
6
8
10
12
14
3*00201 2*01201 1*00901 4*02401 2*02501 BHV-1
MHC class I gene  
(a) 
0
5
10
15
20
3*00201 2*01201 1*00901 4*02401 2*02501 BHV-1
 
MHC class I gene  
(c)
Fig. 3. MHC restriction of the BHV-1 antigen-specific CD8 T cells in
the cell line from animal 3430 (MHCI A10/A15). T cells were incubated
with COS-7 cells that had been co-transfected with ICP4-1 (a), ICP4-2
(b) or Circ (c), along with cDNAs encoding each of the MHCI alleles
expressed by the donor animal. Release of IFNg into the culture
supernatant was measured after 48 h using a specific ELISA. T cells
incubated with autologous T. annulata-transformed cells infected with
BHV-1 were included as a positive control.
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distinct from the sequences of the BoLA molecules included
in the training of the NetMHCpan method, which probably
accounts for the overall low prediction accuracy for these mol-
ecules (see Table 3).
Abundance of epitope-specific CD8 T cells
Although the IFNg ELISA allowed detection of the viral
proteins and the location of the epitopes recognized by CD8
T cells, it did not provide information on the relative abun-
dance of T cells specific for each of the epitopes in the CD8
T-cell lines. Therefore, further experiments were undertaken
to provide an estimate of the proportions of cells that are
specific for the different epitopes. CD8 T-cell lines from one
of the A10/A15 animals (3430) and the A11/A14 animal
(1475) were analysed both by intracellular staining for IFNg
and using an IFNg ELISpot assay. The responses of T cells
against autologous T. annulata-infected cells pulsed with
peptides containing each of the identified epitopes were
compared with the responses of the same cells infected with
BHV-1. Controls included T cells incubated with autolo-
gous T. annulata-infected cells alone or pulsed with an irrel-
evant peptide and MHC-unrelated T. annulata-infected
cells infected with BHV1. The results obtained with both
CD8 T cell lines are illustrated in Fig. 5.
Intracellular IFNg staining of CD8 T cells from the A10/
A15 animal (3430) detected 6.5 and 17.2% positive cells
(following subtraction of background levels) for the ICP4
epitopes presented by 2*00201 (A10) and 2*00901 (A15),
respectively, compared to 54% positive cells reactive with
whole BHV1 (Fig. 5b). The lack of a detectable response to
the Circ epitope recognized by this animal is thought to
reflect a lower frequency of CD8 T cells specific for this epi-
tope and the relative inability of this assay to detect cells
present at a frequency of <1%. Staining of responding CD8
T cells from the A11/A14 animal (1475) detected 6 and
14%positive cells for the ICP4 and Circ epitopes presented
by 3*01701 and 2*01801 (both A11), respectively, compared
to 21% for whole BHV1 (Fig. 5d).
The ELISpot assays yielded much smaller percentages of
positive cells (<1%) in both T-cell lines, but detected sub-
stantial responses, relative to those against the whole virus,
to the same epitopes detected by intracellular IFNg stain-
ing in each animal (Fig. 5a, c). A weaker response to the
Circ epitope recognized by the A10/A15 animal (3430)
was detected in this assay. The ICP22 epitope presented
by 4*02401 (A14) in the A11/A14 animal (1475) was also
included in this assay and yielded a positive result of
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Fig. 4. Fine mapping of the BHV-1 T-cell epitope in ICP4 recognized by CD8 T cells from animal 3109 (A10/A15) restricted by the
1*00901 MHCI allele. T-cell recognition was tested by incubating with autologous T. annulata-infected cells pulsed with individual pepti-
des and measuring IFNg after 48 h using a specific ELISA. The results obtained with 12-mer peptides and 9-mer peptides are shown
in panels (a) and (b), respectively.
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similar magnitude to that detected for the ICP4 and Circ
epitopes.
The results of these experiments indicate that the epitope-
specific T cells detected in these studies represent major
components of the virus-specific CD8 T-cell lines.
DISCUSSION
The current study has, for the first time, provided informa-
tion on the fine specificity of CD8 T-cell responses to a nat-
ural herpesvirus infection in a non-primate species. The
development of a system to generate virus-specific CD8 T-
cell lines from BHV-1 immune cattle, employing Theileria-
transformed cell lines for antigen presentation, has enabled
us to investigate the viral antigens recognized by CD8 T
cells in the current study. Screening of a panel of 16 candi-
date viral gene products with 3 CD8 T- cell lines identified
four antigens, including three IE gene products and a tegu-
ment protein. The epitope-containing regions of these anti-
gens and the respective presenting MHC class I alleles were
identified and semi-quantitative analyses of the epitope-
specificity of the CD8 T-cell lines indicated that the IE anti-
gen epitopes represent a major component of the CD8 T-
cell response to the virus.
Previous analyses of the specificity of immune responses to
BHV-1 have focused largely on a subset of the glycopro-
teins. The gB, gC, gD and gH glycoproteins were shown to
induce readily detectable antibody and/or CD4 T-cell
responses [33, 34], and one previous study reported evi-
dence of recognition of the gC and gD glycoproteins by
CD8 T cells from immune cattle [24]. Animals vaccinated
with a DNA plasmid encoding gB were also shown to gener-
ate a gB-specific CD8 T-cell response [35]. However, the
CD8 T cell lines used in the current study did not have
detectable reactivity with cells transfected with the gB, gC or
gD genes, and in a previous study we showed that the same
cell lines did not recognize cells infected with recombinant
vaccinia viruses expressing these glycoproteins [25]. Previ-
ous antigen screening by Denis et al., [24] was based on
cytotoxicity assays using virus-stimulated whole PBMC as
effectors and was confined to four glycoproteins expressed
Table 2. Mapping of CD8 T-cell epitopes in BHV-1 IE proteins by screening for recognition of truncated peptides
Viral protein/MHC allele T-cell line Peptides Response to peptide†
2 mg 200hg 20hg
ICP4/3*00201 4340 (A10/A15) 399AGPDLQLARL408 76 81 75
400GPDLQLARLL409 57 26 1
400GPDLQLARL408 63 37 3
400GPDLQLAR407 0 1 0
401PDLQLARL408 3 1 0
ICP4/3*01701 1475 (A11/A14) 287GRATGARAGYAA298 25 1 0
286RGRATGARAGYA297 16 3 0
287GRATGARAGYAA298 25 1 0
288RATGARAGYAA298 31 4 0
289ATGARAGYAA298 29 2 0
290TGARAGYAA298 45 13 0
290TGARAGYA297 12 14 3
Circ/3*00201 4340 (A10/A15) 140FTTPEILIELE150 35 39 45
140FTTPEILIEL149 38 26 0
141TTPEILIEL149 37 47 41
141TTPEILIE148 0 0 0
142TPEILIEL149 3 0 0
Circ/2*01801 1475 (A11/A14) 233AAPAPSPGAL242 54 39 nt
234APAPSPGAL242 51 38 nt
234APAPSPGA241 0 0 nt
235PAPSPGAL242 14 12 nt
ICP22/4*02401 1475 (A11/A14) 42RGPGAFCPED51 0 0 0
43GPGAFCPEDW52 87 2 1
44PGAFCPEDW52 88 87 1
45GAFCPEDW52 87 11 1
†The responses of CD8 T-cell lines were examined by incubating T cells with three different concentrations of peptide in duplicate for 48 h and then
testing the supernatants for their ability to up-regulate class II MHC expression in MDBK cells. The results are presented as the percentage of class
II MHC-positive MDBK cells minus background levels obtained with supernatant from unstimulated T cells. Values for the latter varied between 7
and 12% in different assays. The inferred epitope sequences are highlighted in bold. nt = not tested.
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Table 3. Summary of mapping and in silico prediction of CD8 T-cell epitopes in BHV-1 immediate early proteins
Mapped region – the epitope-containing segment of the protein identified by screening overlapping 17mer peptides. Predicted accuracy – the pre-
dicted accuracy reported by NetMHCpan-2.9 for the given BoLA-I molecule. Mapped epitope – the epitope sequence identified by peptide screening.
F-Rank – the false-positive ratio (i.e. the number of peptides with a predicted binding affinity value that is stronger than the known epitope divided by
the number of 8-11mer peptides in the source protein). Alternative epitope – an alternative epitope predicted by NetMHCpan-2.9. F-Rank-alt – the
false-positive ratio for the alternative epitope.
Viral protein Mapped region BoLA-I Mapped epitope Predicted accuracy F-Rank Alternative epitope F-Rank-alt
ICP4 1153–1174 1 : 00901 1159FVEGEAASH1167 0.694 0.271
ICP4 393–414 3 : 00201 399AGPDLQLARL408 0.853 0.004
Circ 136–157 3 : 00201 141TTPEILIEL149 0.853 0.001
ICP4 282–303 3 : 01701 290TGARAGYAA298 0.470 0.078
Circ 229–250 2 : 01801 234APAPSPGAL242 0.334 0.015
ICP22 37–58 4 : 02401 44PGAFCPEDW52 0.853 0.025 45GAFCPEDW52 0.004
0
50
100
150
200
250
300
350
400
Aut BHV Allo BHV ICP4-1 ICP4-2 Circ Cont
S
F
U
 p
e
r 
2
.5
×
1
0
5
 c
e
lls
S
F
U
 p
e
r 
2
.5
×
1
0
5
 c
e
lls
 
Antigen
Animal 3430 
(a)
0
50
100
150
200
250
300
350
400
Aut BHV Allo BHV ICP4 Circ ICP22 Cont
Antigen
Animal 1475
(c)
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
BHV-1 ICP4-1 ICP4-2 Circ Cont
%
 IF
N
g
-p
o
si
tiv
e
 c
e
lls
%
 IF
N
g
-p
o
si
tiv
e
 c
e
lls
Antigen
(b)
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
BHV-1 ICP4-1 Circ Cont
Antigen
(d)
Fig. 5. Antigenic specificity of BHV-1-specific CD8 T-cell lines analysed using an IFNg ELISpot assay (a, c) and by staining for intracel-
lular IFNg (b, d), following stimulation with BHV-1 or T. annulata-transformed cells pulsed with peptides representing each of the iden-
tified CD8 T-cell epitopes. Results are shown for CD8 T-cell lines from animal 3430 (MHC A10/A15) (a, b) and animal 1475 (MHC A11/
A14) (c, d). Autologous and allogeneic cells infected with BHV-1 (Aut BHV and Allo BHV, respectively) were tested in the intracellular
IFNg assay to confirm MHC restriction. A control (Cont) consisting of T. annulata-transformed cells pulsed with an irrelevant peptide
was included in each assay.
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in recombinant vaccinia viruses. The involvement of CD8 T
cells was inferred from ablation of cytotoxicity following
depletion of CD8 T cells by antibody- and complement-
mediated lysis. Since CD8 is also known to be expressed on
bovine NK cells and gd T cells [36, 37], which can exhibit
cytotoxic activity, the attribution of the cytotoxicity mea-
sured in these studies to classical CD8 T cells remains open
to question. Nevertheless, it is possible that CD8 T cells spe-
cific for additional antigens, including the glycoproteins,
were present at low frequency in our T-cell lines, but were
not detected by our screening method. The T-cell lines used
in the present study were depleted of gd T cells and,
although they were not examined for expression of NK cell
markers, the demonstration of exquisite MHC restriction of
the detectable responses clearly showed that they were
mediated by classical CD8 T cells.
It is particularly striking that 3 of the 4 IE gene-encoded
proteins included in the screening panel were recognized
strongly by the CD8 T-cell lines, whereas only 1 of the
remaining 12 E and L gene products gave a positive result in
1 animal. One of the IE genes, ICP4, is only expressed in the
IE phase, whereas the others (Circ and ICP22) also continue
to be expressed during later phases. ICP4 and ICP22 are
known to be components of the protein complex that ini-
tiates transcription of E genes [38], and HSV-1 orthologues
of both have been identified as CD8 T-cell antigens in
humans [12]. The third IE gene (Circ), which does not have
a known orthologue in HSV-1 and is of unknown function,
encodes a myristylated protein found in the cytoplasm of
infected cells [39]. The E gene UL49 encodes a tegument
protein [40], the orthologue of which in HSV-1 and HSV-2
has also been identified as a CD8 T-cell antigen that is par-
ticularly dominant in people expressing the HLA-B*0702
class I allele [12]. Although antigen screening was confined
to proteins encoded by 16 of the 73 BHV-1 open reading
frames, the results indicated pronounced dominance of IE
gene products among the viral proteins that were screened.
All three animals examined recognized epitopes in the ICP4
and Circ proteins and one animal recognized ICP22. More-
over, CD8 T cells specific for these epitopes represented a
substantial component of the CD8 T-cell lines, with 20–
24% of CD8 T cells being found to respond specifically to
the strongest epitopes, based on an intracellular IFNg stain-
ing assay. Given that not all CD8 T cells specific for a given
epitope produce detectable levels of IFNg [41], these figures
are almost certainly an underestimate of the true frequen-
cies. The use of T. annulata-infected cells as antigen-pre-
sented cells to generate the CD8 T-cell lines is unlikely to
have resulted in a preferential bias in the specificity of the
detected response. They express high levels of both class I
and class II MHC proteins on their cell surface and support
fully productive infection with BHV-1, resulting in cell lysis
and release of infectious virus; they also show surface
expression of BHV-1 glycoproteins following infection with
the virus [25]. Hence, they are expected to express the full
repertoire of BHV-1 proteins and present them efficiently
to CD8 T cells.
Six CD8 T-cell epitopes (three in ICP4, two in Circ and one
in ICP22) presented by five different MHCI alleles were
identified within the 3 BHV-1 IE proteins. A combination
of T-cell screening of synthetic peptides and in silico analy-
sis employing the NetMHCpan prediction method was used
for epitope identification. The latter successfully predicted
four of the epitopes identified by peptide screening and
identified an 8-mer peptide, rather than a 9-mer one, as the
more likely identity of the remaining epitope. Further stud-
ies using class I MHC tetramers will be required to unequiv-
ocally confirm the identity of these epitopes. Nevertheless,
the findings highlight the value of these in silico tools for
predicting and refining the identity of CD8 T-cell epitopes.
In two cases, the in silico method gave low prediction accu-
racy for the epitope and BoLA restriction element. The dis-
tinct nature of the amino acid sequences of the two
corresponding BoLA molecules compared to those of the
BoLA molecules included in the training of the NetMHC-
pan method probably account for the overall low prediction
accuracy for these molecules. Further data on the nature of
the peptides that bind to these alleles are likely to improve
the predictive values of NetMHCpan. Such improvements
should facilitate more reliable prediction and more rapid
identification of epitopes in known CD8 T-cell antigens in
future studies.
The results of this study are consistent with previous evi-
dence that CD8 T-cell responses to viral infections are fre-
quently focused on a limited number of dominant epitopes,
which differ depending on host MHC I genotype (reviewed
in [42]). In this regard, it is of note that the two MHCI-
identical, but otherwise unrelated, animals in the current
study had responses to the same three epitopes (two in ICP-
4 and one in Circ), whereas T cells from the third animal,
which had a different MHCI type, recognized different epit-
opes in ICP4 and Circ and additional epitopes in ICP22 and
UL49. Given the influence of MHC type on epitope specific-
ity, it will be necessary to extend these studies to additional
animals of different MHC types to determine whether the
same IE gene products are consistently immunodominant.
CD8 T-cell responses specific for IE gene products are con-
sidered to be particularly relevant for immunity, because
their early expression, before the full effect of virus-medi-
ated down-regulation of class I MHC, should theoretically
enable rapid induction of CD8 T-cell responses following
virus challenge. However, studies of responses to HSV-1 in
humans have identified CD8 T cells that are specific for a
variety of proteins. Laing et al. [12] list 23 CD8 T cell target
HSV-1 proteins, including IE and E gene products as well as
glycoproteins, although individual people only showed
responses to a subset of these, which varied depending on
their MHC type. As pointed out by these authors, the sum-
marized findings represent the results of a large number of
studies of T-cell specificities from both healthy and lesioned
HSV-1-infected people, using different antigen-screening
systems. Both the stage of infection of donors and the T-cell
assays employed could have influenced the particular
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antigens identified. As in the current study, early studies to
screen for HSV-1 antigens used immune CD8 T cells stimu-
lated in vitro with cells incubated with whole live or UV-
irradiated virus (eg. [43]), whereas several more recent
large-scale screening studies examined the ability of large
panels of viral peptides or recombinant proteins to elicit
CD8 T-cell responses in vitro [7, 8]. While the latter
undoubtedly identified genuine antigenic specificities, the
epitopes may not all be presented efficiently by virus-
infected cells and hence the findings do not necessarily
reflect the frequencies of cells capable of recognizing
infected cells and acting as effectors. An extreme example of
this is the EBV EBNA1 protein, which inhibits its own pro-
teasomal degradation, resulting in the failure of CD8 T cells
to recognize epitopes from this protein on virus-infected
cells [44], yet CD8 T cells specific for the antigen can be
detected by other screening methods [45]. The frequencies
of CD8 T-cell antigen specificities might also be influenced
by whether they are examined during active infection or fol-
lowing convalescence, and whether subjects have received
repeated viral challenge. In this regard, the CD8 T-cell lines
examined in the current study were derived from blood T
cells harvested 15 days after virus challenge of animals pre-
viously vaccinated with a live attenuated vaccine. Previous
longitudinal studies of CD8 T-cell responses to human
CMV and EBV indicated that the range of CD8 T-cell spe-
cificities remains relatively stable over time [13, 46, 47],
although in some instances a less pronounced dominance
hierarchy has been observed in the memory pool compared
to the active response [48]. It is possible that the detection
in the current study of prominent responses to BHV-1 IE
proteins reflects preferential expansion of pre-existing
memory T cells specific for the IE antigens in the 15-day
period immediately following virus challenge.
In conclusion, the current study has for the first time pro-
vided unambiguous information on the identity of BHV-1
viral proteins recognized by specific CD8 T-cell responses,
yielding evidence that three of the IE gene products are
dominant targets. Since memory CD8 T cells specific for IE
gene products would be expected to be effective in minimiz-
ing virus production following challenge of immune ani-
mals and upon reactivation of latent infection, these
antigens provide potentially useful candidates for the gener-
ation of a subunit vaccine for BHV-1, should such a vaccine
be required.
METHODS
Viruses
The Cooper and Iowa strains of BHV-1 used in the study
(kindly provided by Moredun Scientific, Roslin, UK) and
the methods used to culture and quantify the virus are
described elsewhere [25]. All of the in vitro analyses of T-
cell responses used the Cooper strain.
Animals and immunization
Three Holstein cattle aged approximately 18months and
screened as BHV-1-negative at the outset of the experiments
were used in the study. Their MHC class I types were deter-
mined using a combination of serological typing with
monoclonal antibodies [49] and allele-specific PCR [50].
The animals were vaccinated with a live attenuated BHV-1
vaccine (Tracherine IBR marker live, Pfizer Animal Health,
Surrey, UK). One of them (1475) was challenged
intranasally 2 months later with wild-type BHV-1 (2107
TCID50 Cooper strain). The remaining two animals were
challenged twice with wild-type BHV-1, first with 2107
TCID50 Iowa strain 4weeks after vaccination, and then after
a further 2 years with 2107 TCID50 Cooper strain, both
administered intranasally. CD8 T-cell responses were stud-
ied using blood leukocytes collected 15 days after the final
challenge. Cell lines transformed by infection with Theileria
annulata were established from each animal at the outset of
the study by in vitro infection of peripheral blood mononu-
clear cells (PBMC) with the sporozoite stage of the parasite,
as described previously [51].
BHV-1-specific CD8 T-cell lines
The method used for establishing CD8 T-cell lines specific
for BHV-1 is described in detail elsewhere [25]. Briefly, ali-
quots of 4106 PBMC from immunized animals were cul-
tured in 24-well plates with 2105 gamma-irradiated
autologous T. annulata-infected cells infected with BHV-1.
Viable cells harvested after 7 days were subjected to a second
stimulation with irradiated BHV-1-infected cells and, after a
further 7 days of culture, viable cells were again harvested
and enriched for CD8 T cells by antibody- and comple-
ment-mediated depletion of CD4 and gd T cells. The CD8-
enriched populations (>97% pure) were then subjected to a
further stimulation at a ratio of 10 : 1 BHV-1-infected cells
to T cells, with addition of 100Uml 1 recombinant human
IL-2 (Chiron, Emryville, CA, USA).
Isolation and cloning of BHV-1 genes
PCR primers containing a KOZAK sequence were designed
to amplify full-length sequences of the selected BHV-1
genes, such that the stop signal was removed. A PCR proto-
col designed to amplify GC-rich DNA was employed, using
the conditions described by Hansen and Justesen [52]. PCR
reactions were performed in a volume of 50 µl containing
1 µl 25mM DNTP mix, 1 µl 20 pmolml 1 primer stock, 1 µl
50mM MgCl2, 5 µl 10 PCR buffer, 1 µl template DNA
and 0.5 µl Taq DNA polymerase (Bioline, UK). PCR reac-
tions were tested with or without DMSO at 5% (v/v) and
with Betaine solution (Sigma, Dorset, UK) at 1 or 2M con-
centration in order to obtain the most PCR product. The
conditions that worked best for most reactions were 5%
DMSO and 1 or 2M Betaine.
PCR reactions were performed on a Techne Thermal cycler
(Bibby Scientific, UK) with the following settings: 95

for
1min, then 30 cycles of 95

1min, annealing for 1min,
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72

C for 1min/kb, followed by 72

for 10min. If the PCR
product contained a single band, the product was purified
using a Qiaquick PCR purification kit (Qiagen Ltd, UK) as
described. If the product contained multiple bands, the
band of the correct size was gel-purified using a Qiagen gel
purification kit (Qiagen Ltd, UK) as described.
The purified PCR product was then cloned into the expres-
sion vector pcDNA3.1V5 His TOPO according to the man-
ufacturer’s instructions. Positive colonies were selected by
colony PCR and plasmid DNA for transfection was pre-
pared using a Qiagen mini prep kit according to the manu-
facturer’s instructions (Qiagen Ltd, UK).
Antigen screening
Antigen screening was carried out essentially as described
previously [53], and was based on measurement of inter-
feron gamma (IFNg) release by CD8 T-cell lines incubated
with COS-7 cells transfected with individual BHV-1 genes
along with a pool of cDNAs encoding the class I heavy
chains expressed by the respective animals. COS-7 cells
were plated at 2104 cells per well in 96-well flat-bottom
plates in Dulbecco’s modified Eagle’s medium (DMEM)
with 10% foetal bovine serum, 2mM L-glutamine, 100 u
penicillin and 10 µg streptomycin/ml. The following day the
cells were transfected with 100 ng of BHV-1 DNA, 100 ng
bovine class I DNA and 0.9 µl of FuGENE (Roche Diagnos-
tics) in 50 µl of DMEM without additives for 4 h at 37

C.
The transfection medium was then replaced with 200 µl
DMEM and the cells were incubated for 24 h at 37

C.
1104CD8 T cells in 150 µl of RPMI growth medium were
then added to each well and the plates incubated for a fur-
ther 24 h prior to the removal of 100 µl of medium for IFNg
detection.
Mapping of CD8 T-cell epitopes
A combination of two methods was used to locate and iden-
tify the epitope(s) recognized by immune CD8 T cells. First,
cloned fragments of the positive cDNAs obtained by PCR
amplification were screened for recognition, as described
for the full-length cDNAs, in order to localize the epitopes
to one discrete region. Overlapping synthetic peptides
(17mers overlapping by 12 residues; Pepscan Ltd, Nether-
lands) representing the positive region were then screened
to identify the epitope using T. annulata-infected cells as
antigen-presenting cells (APC), as described previously
[53]. Assays were conducted in 96-well flat-bottomed plates
using 2104CD8 T cells/well, with 104 peptide-pulsed
APC, in a total volume of 200 ul and incubated for 48 h at
37

C. Supernatants were assayed for IFNg as a measure of
recognition by the CD8 T-cell line. The minimum peptide
length recognized by the T cells was then determined by
measuring responses to 10-fold dilutions of peptides of dif-
ferent lengths covering the region identified by the positive
17-mer peptides. Mapping of one of the epitopes (restricted
by the 1*00901) used peptide-pulsed APC, as described
above, whereas mapping of the remaining epitopes mea-
sured responses to peptides added directly to the CD8 T
cells. Preliminary experiments indicated that these methods
had similar sensitivity (data not shown).
Epitope prediction
An in silico validation of the identified epitopes and corre-
sponding BoLA restriction elements was performed using
the NetMHCpan prediction method [28]. This method is
trained on an extensive set of close to 140 000 MHC-peptide
binding values covering 158 MHC molecules, including 13
bovine MHC class I (BoLA-I) alleles, and allows for predic-
tion of peptides capable of binding to any MHC class I mol-
ecule of known protein sequence. NetMHCpan version 2.9
[30] was used rather than the recently updated version 3.0
[54], as the former was trained on an extended set of BoLA-
I binding data that are not available in the public-domain
data used to train version 3.0.
Measurement of IFNg release
All of the experiments conducted with full-length viral
genes to screen for antigen recognition and MHC restric-
tion, as well as those using peptides to map the 1*00901-
restricted CD8 epitope, measured IFNg release in culture
supernatants using a sandwich ELISA in Immulon 4HBX
flat-bottomed microtitre ELISA plates (Thermo Fisher Sci-
entific, Roskilde, Denmark), using non-competing mono-
clonal antibodies specific for bovine IFNg (clones CC330
and CC302; AbD Serotec, Kidlington, UK). The latter was
conjugated with biotin, and binding was detected with
horseradish peroxidase-conjugated streptavidin (AbD; Sero-
tec, UK), followed by addition of TMB (3, 3¢, 5, 5¢-tetrame-
thylbenzidine) substrate solution (BD Biosciences, Oxford,
UK). A standard curve for determining IFNg concentra-
tions was generated using a series of doubling dilutions of
bovine IFNg (AbD; Serotec, UK). The IFNg concentration
was then calculated by correlation to the standard curve
generated by the IFNg standards. In the remaining epitope-
mapping experiments, IFNg release by T cells was measured
using a biological assay performed as described previously
[53], based on the ability of the IFNg in culture superna-
tants to up-regulate surface expression of MHC class II on
Madin–Darby bovine kidney (MDBK) cells. In preliminary
studies, we showed that this assay had slightly greater sensi-
tivity than the ELISA (data not shown).
Interferon g ELISpot
ELISpot analysis was performed using Multiscreen IP filter
plates (Millipore with PVDF membrane) using the protocol
described by Millipore (EDM Millipore, UK). The plates
were coated using an anti-IFNg monoclonal antibody
(CC330, AbD Serotec, UK) at 10 µgml 1 and incubated
overnight at 4

C. After the membrane was washed and
blocked, two-fold dilutions of the effector CD8 T cells were
added to triplicate wells, ranging from 5103 to 1.25103
cells per well. Stimulator cells, consisting of T. annulata-
infected cells either infected with BHV-1 or pulsed with
peptide, were added at an effector:stimulator ratio of 1 : 10;
effector cells alone and T. annulata-infected cells without
peptide or pulsed with an irrelevant peptide were included
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as negative controls. After 24 h incubation at 37

C, the cells
were removed and the plates washed before the secondary
biotinylated anti-IFNg monoclonal antibody (CC302,
Serotec) was added at 2 µgml 1. After incubation at 37

C
for 2 h, the plates were washed and an alkaline phosphatase-
conjugated streptavidin (Serotec, UK) was added at a
dilution of 1/1000. After 45min incubation at room
temperature, the streptavidin was removed and the wells
washed before addition of BCIP/NBT substrate (Sigma fast
BCIP/NBT tablet, Sigma). The wells were then incubated
for 5–10min before being washed under running water and
dried overnight in the dark. Spots on the plates were
counted and analysed using an Elispot reader (AID Strass-
berg, Germany).
Intracellular cytokine staining for IFNg
Intracellular cytokine staining for IFNg was used in order
to quantify the number of cells responding to particular
viral antigens. The responding CD8 T cells were incubated
for 2 h with stimulator cells (T. annulata-infected cells
infected with BHV-1 or pulsed with peptide) at a responder:
stimulator ratio of 1 : 5–1 : 10 before Brefeldin A was added
at a concentration of 10 µgml 1. After a further 2 h incuba-
tion at 37

C, the cells were washed twice in PBS and (if
required) stained for CD8 using a specific FITC-conjugated
antibody (CC63;Serotec, UK) or an isotype control, before
being fixed in 2% paraformaldehyde. The cells were then
permeabilized in permeabilization solution 2 (Becton–Dick-
inson, CA, USA) and stored overnight at 4

C in PBS con-
taining 0.1% sodium azide. The following day, the cells
were stained using an RPE-conjugated anti-IFNg antibody
(CC302, serotec) or an isotype control antibody and ana-
lysed using a FACScalibur flow cytometer (Becton–Dickin-
son, CA, USA).
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